Figure 1.

LEGENDScreen™ analysis of adalimumab treated RA patients (cross-sectional cohort) identifies differences between ADA⁺ and ADA⁻ individuals. PBMCs from patients treated with adalimumab defined as ADA⁺ (n = 10) or ADA⁻ (n = 10) were stained with LEGENDScreen™ for 332 cell surface markers, in addition to antibodies against CD19, CD4 and CD24 and CD38. Heatmaps showing average frequency expression of each LEGENDScreen™ marker for each sample group (ADA⁺ and ADA⁻) for PBMCs (A), and CD4⁺T cells and CD19⁺B cells (B). Markers are ranked according to expression in ADA⁻ patients. Volcano plot showing fold-change of frequency expression between patient groups (ADA⁻/ADA⁺) (Log₂) and p-value (t-test) (Log₁₀), no markers passed the Holm-Sidak post-hoc test. Blue circle: significantly down-regulated markers; red circle significantly up-regulated markers, in ADA⁻ vs. ADA⁺; (C) for CD4⁺T cells and CD19⁺B cells, and (D) mature (CD24^intCD38^int), immature (CD24^hiCD38^hi), and memory (CD24^hiCD38^lo) B cells.